Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 86

1.

Subcutaneous trastuzumab (Herceptin) injection shows promise.

[No authors listed]

Oncology (Williston Park). 2012 Sep;26(9):873. No abstract available.

2.

Subcutaneous trastuzumab (Herceptin). Ready to use, but more serious adverse effects than intravenous (IV) trastuzumab.

[No authors listed]

Prescrire Int. 2015 Apr;24(159):93. No abstract available.

PMID:
25941697
3.

Herceptin (trastuzumab): adjuvant and neoadjuvant trials.

Yaal-Hahoshen N, Safra T.

Isr Med Assoc J. 2006 Jun;8(6):416-21. Review. No abstract available.

4.

Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort.

Gianni L, Eiermann W, Semiglazov V, Lluch A, Tjulandin S, Zambetti M, Moliterni A, Vazquez F, Byakhov MJ, Lichinitser M, Climent MA, Ciruelos E, Ojeda B, Mansutti M, Bozhok A, Magazzù D, Heinzmann D, Steinseifer J, Valagussa P, Baselga J.

Lancet Oncol. 2014 May;15(6):640-7. doi: 10.1016/S1470-2045(14)70080-4. Epub 2014 Mar 20.

PMID:
24657003
5.

Subcutaneous herceptin therapy.

O'Donoghue N, Quintyne KI, Woulfe B, Gupta R, O'Reilly S.

J Clin Pharmacol. 2013 Dec;53(12):1341-2. doi: 10.1002/jcph.171. Epub 2013 Sep 21. No abstract available.

PMID:
23996323
6.

HER2-positive breast cancer: update on Breast Cancer International Research Group trials.

Nabholtz JM, Reese DM, Lindsay MA, Riva A.

Clin Breast Cancer. 2002 Oct;3 Suppl 2:S75-9. Review.

PMID:
12435291
7.

An appraisal of subcutaneous trastuzumab: a new formulation meeting clinical needs.

Launay-Vacher V.

Cancer Chemother Pharmacol. 2013 Dec;72(6):1361-7. doi: 10.1007/s00280-013-2289-4. Epub 2013 Sep 22.

PMID:
24057040
8.

Reply to: letter to the editor "subcutaneous herceptin therapy".

Wynne C, Harvey V, Schwabe C, Waaka D, McIntyre C, Bittner B.

J Clin Pharmacol. 2013 Dec;53(12):1343-4. doi: 10.1002/jcph.172. Epub 2013 Sep 21. No abstract available.

PMID:
23996383
9.

Trastuzumab-based neoadjuvant therapy in patients with HER2-positive breast cancer.

Chang HR.

Cancer. 2010 Jun 15;116(12):2856-67. doi: 10.1002/cncr.25120. Review.

10.

Trastuzumab for patients with HER2 positive breast cancer: delivery, duration and combination therapies.

Pinto AC, Ades F, de Azambuja E, Piccart-Gebhart M.

Breast. 2013 Aug;22 Suppl 2:S152-5. doi: 10.1016/j.breast.2013.07.029. Review.

PMID:
24074778
11.

[Breast cancer: adjuvant therapy with trastuzumab: herceptin adjuvant (HERA) Trial Study, B-31- and N9831-Study].

Mallmann P.

Internist (Berl). 2006 Nov;47(11):1183-5. German. No abstract available.

PMID:
17048017
12.

[Adjuvant therapy with trastuzumab (Herceptin) in primary breast cancer].

Huober J, Jackisch C, Untch M, Möbus V, Wallwiener D, Kaufmann M, Minkwitz G.

Zentralbl Gynakol. 2006 Feb;128(1):30-7. German.

PMID:
16450285
13.

Neoadjuvant trastuzumab for breast cancer. Better to stick with proven treatments.

[No authors listed]

Prescrire Int. 2013 Feb;22(135):39. Review.

PMID:
23444499
14.

Ongoing adjuvant trials with trastuzumab in breast cancer.

Tan AR, Swain SM.

Semin Oncol. 2003 Oct;30(5 Suppl 16):54-64. Review.

PMID:
14613027
15.

Comparison of subcutaneous and intravenous administration of trastuzumab: a phase I/Ib trial in healthy male volunteers and patients with HER2-positive breast cancer.

Wynne C, Harvey V, Schwabe C, Waaka D, McIntyre C, Bittner B.

J Clin Pharmacol. 2013 Feb;53(2):192-201. doi: 10.1177/0091270012436560.

PMID:
23436264
16.

Can NOAH guide us to improved survival in breast cancer?

Johnston SR.

Lancet Oncol. 2014 May;15(6):550-2. doi: 10.1016/S1470-2045(14)70116-0. Epub 2014 Mar 20. No abstract available.

PMID:
24657002
18.

Development and clinical overview of trastuzumab (herceptin).

Frankel C.

Semin Oncol Nurs. 2000 Nov;16(4 Suppl 1):13-7. Review.

PMID:
11151453
19.

As treatment options progress, so must we.

Harmer V.

Br J Nurs. 2013 May 23-Jun 12;22(10):S3. No abstract available.

PMID:
23752364
20.

Does trastuzumab increase the risk of isolated CNS metastases in patients with breast cancer?

Abrey LE.

Nat Clin Pract Neurol. 2006 Jun;2(6):302-3. No abstract available.

PMID:
16932571

Supplemental Content

Support Center